Back

Argus Research starts 10x Genomics coverage with Buy rating, 28% upside

Verifying
  • Argus Research initiated coverage of 10x Genomics with a Buy rating.
  • $110 price target implies 28% upside from the stock's price around $85.
  • 10x Genomics shares traded above their 50-day and 200-day moving averages.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.